South Australians at high risk of acquiring HIV will have the opportunity to benefit from PrEP treatment
Alfred Health in Victoria has partnered with the South Australian Health and Medical Research Institute (SAHMRI), SA Health and local clinics for a new study to begin in April this year.
The study follows the announcement of the Pre-Exposure Prophylaxis (PrEP) access trial late last year.
SAHMRI’s Executive Director, Professor Steve Wesselingh says the PrEP trial is an important step towards preventing HIV among South Australians at high risk of contracting the infection.
“Over the last five years, there has been close to 60 new HIV infections in South Australia each year,” Professor Wesselingh says.
“PrEP is an antiretroviral medication take daily by people at the highest risk of HIV to prevent them from acquiring HIV. PrEP has been shown internationally and nationally to reduce the number of new cases and we hope the same success will occur here in South Australia.”
Associate Professor Edwina Wright from Alfred Health says the PrEP study in South Australia will draw from the successful Victorian version, which has been underway since July last year.
“We are excited for the opportunity to work with South Australia to build a PrEP response that specifically meets the needs of South Australians by working closely with clinicians, local sexual health clinics and the community.”